Falsification and Pharmacovigilance: What Do Patients Get to See and What Should They Do with It?

By:
Posted: 03/18/2014

 Are we really ‘enabling patients to act appropriately’?

The ‘Falsified medicines directive’ (2011/62/EU) and the ‘Pharmacovigilance regulation’ (No 1235/2010) will influence some of the information that patients receive about medicines. In both the directive and the regulation, several forms of visual communication are mentioned. Dr Karel van der Waarde thinks that it is unlikely that a modification in the visual presentation has much influence on these actions of people. In this discussion piece Dr Karel van der Waarde explores the impact of the latest falsification and pharmacovigilance regulation on pharmaceutical packaging.

By Dr Karel van der Waarde, Pharmaceuticals Consultant and Graphic Design Researcher Independent

Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

By:
Posted: 03/18/2014

Pharma IQ Members